The firm said that it is working with partners to provide collection devices that can be used at home, making it easier for people to gain access to tests.
The firm said that the system's automation and flexibility will help centers be more productive within a testing specialty that can require extensive hands-on time.
The NEO Iris instrument uses the company's Capture solid phase technology for antibody screening and identification, and can run up to 60 tests and screens per hour.
OncoCell aims to enter the cancer prognostic space with its noninvasive immuno-genomics RNA transcriptomics prognostic platform to help differentiate patients with aggressive forms of prostate cancer from patients with indolent disease.